Long-term outcome of NPM1 mutated acute myeloid leukemia: A single-institution experience

Am J Hematol. 2017 Feb;92(2):E17-E18. doi: 10.1002/ajh.24601. Epub 2016 Dec 7.

Authors

Hamid Sayar¹, Parvaneh Bashardoust², Larry Cripe¹, Sujata Chakraborty³, Shaochun Bai³

Affiliations

¹ Indiana University Simon Cancer Center Indiana, University School of Medicine, Indianapolis, Indiana.
² Oceania University of Medicine Apia, Tuamasaga, Western Samoa.
³ Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana.

PMID: 27813149
DOI: 10.1002/ajh.24601

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Female
Humans
Leukemia, Myeloid, Acute / drug therapy
Leukemia, Myeloid, Acute / genetics*
Leukemia, Myeloid, Acute / mortality*
Leukemia, Myeloid, Acute / pathology
Male
Mutation*
Nuclear Proteins / genetics*
Nucleophosmin
Prognosis
Recurrence
Remission Induction

Substances

NPM1 protein, human
Nuclear Proteins
Nucleophosmin